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Moxiﬂoxacin is a broad-spectrum antibacterial 8-methoxy-ﬂuoroquinolone. In order to evaluate the pharmacokinetic properties
of moxiﬂoxacin in mouse plasma and brain tissue, we developed a high-performance liquid chromatography (HPLC) method.
This study was based on single-drug delivery, intravenously dosed in a central listeriosis murine model. The method employed a
reversed-phase Lichrospher RP-18 with a precolumn (250 × 4.6mm) and a mobile phase composed of a mixture of acetonitrile,
methanol, and citric buﬀer (pH = 3.5) with sodium dodecyl sulfate and tetrabutylammonium bromide. Fluorescence detection
was performed at an excitation wavelength of 290nm and an emission wavelength of 550nm. The relative standard deviation
of intra- and inter-day assays was <10%. This validated method led to a short retention time (8.0min) for moxiﬂoxacin. The
standard curves were linear from 5–250µg/L in plasma and from 0.1–2.5µg/g of brain tissue. The limits of quantiﬁcation were
5µg/L in plasma and 0.1µg/g in brain tissue. The method enabled the detection of systemic antimicrobial in plasma and in CNS
in Listeria-infected mice. Injected moxiﬂoxacin passed through the encephalic barrier within a 30 to 60 min after injection time
frame. Moxiﬂoxacin pharmacokinetics are modeled in an infected model compared to control mice.
1.Introduction
Moxiﬂoxacin(1-cyclopropyl-6-ﬂuoro-1,4-dihydro-8-metho-
xy-7-[(4aS.7aS)-octahydro-6H-pyrrolo-[3,4-b]pyridin-6-yl]-
4-oxo-3-quinolinecarboxylic acid hydrochloride, BAY 12-
8039) is a ﬂuoroquinolone molecule with a broad antibacte-
rial spectrum of activity encompassing gram-negative and
gram-positive bacteria [1, 2].
Listeria monocytogenes is a gram-positive bacterium that
is widespread in the environment [3]. It is a facultative
intracellular food-borne pathogen that causes severe and
life-threatening infections, especially septicemia, abortions,
and central nervous system (CNS) infections [3]. Listeriosis
mainly occurs in high-risk groups, including individuals
with severe underlying diseases or with impaired immunity
[4]. Importantly, moxiﬂoxacin has rapid bactericidal activity
against extracellular and intracellular L. monocytogenes [5];
consequently, this drug can be considered more eﬀective
than amoxicillin, the reference treatment, which is only
bacteriostatic against L. monocytogenes [6]. Moreover, Grayo
et al. determined minimal inhibitory concentrations (MICs)
for a large collection of L. monocytogenes strains and did
not detect any that were resistant, regardless of their origin
[5]. Secondly, they conﬁrmed that moxiﬂoxacin has rapid
in vivo activity against L. monocytogenes in BALB/c mice
[7]. To assess the eﬃciency of moxiﬂoxacin in this murine
model of central listeriosis [7], a pharmacokinetic study of
this ﬂuoroquinolone in plasma and brain was necessary.2 Journal of Analytical Methods in Chemistry
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Figure 1: Chemical structures of the ﬂuoroquinolones: (a) moxiﬂoxacin (1-cyclopropyl-6-ﬂuoro-1,4-dihydro-8-methoxy-7-[(4aS.7aS)-
octahydro-6H-pyrrolo-[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid hydrochloride, BAY 12-8039); (b) ciproﬂoxacin (internal
standard).
Indeed, some results can even be misleading: fosfomycin has
recently been declared eﬀective against L. monocytogenes in
vivo, whereas it is not in vitro [8].
In plasma, moxiﬂoxacin quantiﬁcation methods have
been performed to clarify its clinical eﬃcacy [9–12]. Due to
the intracellular development of L. monocytogenes,i ts e e m s
more relevant to measure moxiﬂoxacin concentrations in
CNS tissue rather than in cerebrospinal ﬂuid (CSF) [13,
14]. However, no bioanalytical assay has been performed
to determine moxiﬂoxacin concentrations in brain tissue
(CNS). Thus, we developed a high-performance liquid chro-
matographic (HPLC) method for the determination of mox-
iﬂoxacin in plasma and brain. Our method was then utilised
to evaluate the pharmacokinetic parameters of moxiﬂoxacin
in plasma and brain in a validated murine model of CNS
listeriosis.
2. Experimental
2.1. Chemicals and Reagents. Moxiﬂoxacin (Figure 1(a))a n d
ciproﬂoxacin (Figure 1(b))w e r ep u r c h a s e df r o mB a y e r
Pharma (Germany and France). Prolabo (Fontenay-sous-
Bois/France) provided analytical-grade (Normapur) dipo-
tassium hydrogenphosphate, potassium dihydrogenphos-
phate and orthophosphoric acid (85%). Sigma (Saint Quen-
tinFallavier,France)providedthetetrabutylammoniumbro-
mide (TBABr). Graded acetonitrile and methanol were pur-
chased from Prolabo.
Stock solutions of moxiﬂoxacin HCl and ciproﬂoxacin
were in methanol (1g/L): working standard solutions and
working internal solutions were in methanol (3mg/L).
Citric buﬀer consisted of 25mM citric acid, 10mM
sodium dodecyl sulfate (SDS), and 10mM TBABr in 500mL
water; the pH was adjusted to 3.5 with 0.1M NaOH.
2.2. Instrumentation. Chromatographic analysis was per-
formed on a HPLC system consisting of a pump (LC
10A, Shimadzu, Touzart et Matignon, France), thermostat
(maintained at 25◦C) 717 Plus autosampler Waters, and a RF
551 ﬂuorescence detector (Shimadzu, Touzart et Matignon,
France).Separationwasexecutedbyareversed-phaseLichro-
spher C18 precolumn and column (250 × 4mm, 5µm)
(Merck, Darmstadt, Germany). All data were analyzed using
Chromeleon (version 6.7). The mobile phase consisted of
an acetonitrile-methanol-buﬀer mixture (pH 3.5) (40:3:57,
v/v/v) at a ﬂow rate of 1.0mL/min. Fluorescence detection
was performed at an excitation wavelength of 290nm and an
emission wavelength of 550nm.
2.3. Sample Preparation. To 100µL of plasma or brain (0.5g
crushed in 0.5mL of water), 20µL of the working internal
standard solution was added. The samples were depro-
teinized with acetonitrile (100µL). After centrifugation
(3000rpm for 10 minutes), the supernatant (100µL) was
mixed with sterile water (400µL); ﬁnally, 20µL of this solu-
tion was injected into the chromatographic system.
For the brain, as described above, we added the cipro-
ﬂoxacin solution (20µL) to 100µL of crushed brain. Then,
repeating the plasma sample process, 20µL of the solution
was injected into the chromatographic system.
2.4. Method Validation. Validation experiments were de-
signedaccordingtothe“Guidance forIndustry-bioanalytical
Method Validation,” recommended by the US Food and
Drug Administration (FDA) [15, 16]. The speciﬁcity of the
method was evaluated by assaying mouse blank plasma (n =
48)andmousebraintissue(n = 6)fromseparateanimals.As
validation of the method was performed in human plasma
and experiments performed in mouse plasma, composition
of control mice, and human plasma samples was previously
compared.
The assay was considered satisfactory if precision, ex-
pressed as relative standard deviation (RSD) or coeﬃcient
of variation (%CV), was less than 15% for within- and
between-run variation. Quality control samples were inde-
pendently prepared from the calibration standards, accord-
ing to Section 2.4. The samples contained three diﬀerent
concentrations of moxiﬂoxacin: near the lower limit of
quantiﬁcation (LOQ), mid-point of the concentration range
and near the upper LOQ. Two replicates of each control
sample were processed and analyzed over three validation
days. The assay precision has been calculated using the RSD
and a one-way analysis of variance. The RSD for the lower
LOQ was set at <20%.
Linearity was assessed by plotting calibration curves
in human plasma and duplicated in three separate runs.Journal of Analytical Methods in Chemistry 3
Calibration was done by spiking diﬀerent moxiﬂoxacin
concentrations in plasma and CNS tissue with solutions:
between 5 and 250µg/L (5, 10, 50, 75, 100, 150, 175, 200,
and 250µg/L) and between 0.1 and 2.5µg/g of brain (0.1,
0.5, 0.75, 1.0, 1.5, 1.75, 2.0, and 2.5µg/g of brain). The
curves were ﬁtted by a linear regression method through
measurement of the peak area ratio of moxiﬂoxacin into the
internal standard solution.
Recovery of moxiﬂoxacin was determined by comparing
the postextraction quality control samples mean peak area
ratio to the mean of the methanol standards (n = 9).
Recovery was determined in three diﬀerent runs at three
concentrations (quality controls).
Moxiﬂoxacin stability was acquired by analyzing repli-
cates (n = 3) at three diﬀerent concentrations (quality
control samples). The following stability conditions were
evaluated for each method: long-term stability at −20◦C,
−80◦C, three freeze-thaw cycles, and 18h after sample
treatment in the autosampler. An interval of ±15% on either
side of the initial concentration was applied to assess analyte
stability.
2.5. Pharmacokinetic Application
2.5.1. Experimental Models. BALB/c female mice, 7-8 weeks
old, purchased from Elevage Janvier (Le Genest-St- Isle,
F r a n c e )w e r eu s e d .T h ev i r u l e n ts t r a i nL. monocytogenes
EGDe [17] was provided by the bacteriology laboratory of
the Pasteur Hospital (Paris, France) and used to induce liste-
riosis in these animals.
Mice were weighed (23 to 27g), then injected intra-
venously via the lateral tail vein with 1 × 105 L. mono-
cytogenes in 0.5mL of saline isotonic solution to induce
listeriosis. At 36 hours after infection, mice were treated with
an intraperitoneal (i.p.) injection of moxiﬂoxacin (50mg/kg,
0.1mL). This protocol was approved by the Animal Welfare
Committee of the Pasteur Institute.
2.5.2. Sample Collection. The pharmacokinetic proﬁles of
moxiﬂoxacin in mouse plasma and brain tissue (infected
or not) were analyzed immediately after a single dose of
moxiﬂoxacin. Moxiﬂoxacin concentrations were measured
from samples collected at 0, 5, 15, 30, 60, 120, 240, 360, and
480 minutes after a single-drug injection. At each sampling
time, 6 animals per group were sacriﬁced.
Brains were washed in sterile saline to clear the circu-
lating blood, then dried, weighed (0.5g ± 0.01g), crushed,
and homogenized aseptically and centrifuged. Plasma was
obtained from blood by centrifugation. Cerebral super-
natants and plasma samples were frozen immediately and
stored at −80◦C until analysis.
2.5.3. Pharmacokinetic Analysis. Concentration time data
were analyzed using a noncompartmental model with zero-
order absorption and ﬁrst-order elimination via a nonlinear
least squares technique. Pharmacokinetic parameters were
estimated through standard methods. Maximal plasma and
brain concentrations (Cmax) were determined directly by
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Figure 2: Chromatogram of moxiﬂoxacin (retention time = 8.0
min) and the internal standard ciproﬂoxacin (retention time =
6.0min) in plasma (concentration = 250µg/L).
inspection of the experimental concentration time curves,
the values for the area under the concentration time curve
(AUCt) were calculated by using the trapezoidal rule until
the last concentration was measured. Penetration rate (AUC
brain/AUC plasma) and the ratio sizing pharmacokinetic
parametervariationsbetweencontrolandinfectedmicewere
also calculated. Results are expressed as means ± standard
deviation.
3. Results
3.1. Validation of the Method. Following the assay condi-
tions described above, moxiﬂoxacin was separated from the
internal standard, ciproﬂoxacin; retention times, were 6.0
and8.0minutes,respectively(Figure 2).Thechromatograms
obtained from the analysis of two blank matrices show no
interfering peaks with the same retention times and no
interfering peak was observed for the retention times of the
two ﬂuoroquinolones from human plasma, mouse plasma,
and mouse brain. The resolution between ciproﬂoxacin and
moxiﬂoxacin was up to 2.
The calibration curve obtained by plotting peak: area
ratio (moxiﬂoxacin/internal standard) versus concentration
was linear over the range 5 to 250µg/L in plasma and 0.1
to 2.5µg/g in cerebral tissue. Linearity was observed in our
moxiﬂoxacin analyses from plasma and brain tissue (r2 =
0.999 for both) over the evaluated concentration ranges.
The plasma quantiﬁcation lower limit was 5.0µg/L and
0.1µg/gforbrain,matchingthecalibrationcurvesﬁrstpoint.
Excellent results were obtained for precision (CV < 10%;
CV < 5%) and accuracy (99.2–111.5%; 94.8–106.2%) for
plasma and brain tissue, respectively (n = 6f o re a c hc o n t r o l ;
Tables 1(a) and 1(b)).
The mean moxiﬂoxacin extraction recovery from plasma
and cerebral tissue was above 75% (data not shown). The
stability experiment was carried out under four conditions.
Triplicates of each quality control sample were analyzed.
Specimens stored at −20◦Ca n da t−80◦C were stable for
at least 4 months (data not shown). Moxiﬂoxacin remained
stable over three freeze-thaw cycles (between-run variation4 Journal of Analytical Methods in Chemistry
Table 1: Reproducibility of moxiﬂoxacin plasma concentration (a) and brain tissue concentration (b) measurements: assay performance
data (n = 6).
(a)
Nominal concentration
(µg/L)
Measured
concentration
(µg/L)
Coeﬃcient of variation
(%)
Accuracy
(%)
Measured
concentration
(µg/L)
Coeﬃcient of variation
(%)
Accuracy
(%)
Within-run Between-run
20 22.3 ± 0.3 1.5 111.5 19.9 ± 1.9 9.5 99.0
125 125.5 ± 1.3 1.0 100.4 125.6 ± 2.8 2.2 100.5
225 240.4 ± 3.6 1.5 106.8 230.9 ± 8.1 3.5 102.6
(b)
Nominal concentration
(µg/g)
Measured
concentration
(µg/g)
Coeﬃcient of variation
(%)
Accuracy
(%)
Measured
concentration
(µg/g)
Coeﬃcient of variation
(%)
Accuracy
(%)
Within-run Between-run
0.2 0.19 ± 0.01 3.6 94.8 0.21 ± 0.01 5.0 105.5
1.25 1.33 ± 0.03 2.5 106.2 1.30 ± 0.04 3.0 104.3
2.25 2.17 ± 0.03 1.4 96.6 2.26 ± 0.11 5.0 100.4
Table 2: Plasma and cerebral pharmacokinetic parameters after intraperitoneal administration of moxiﬂoxacin (50mg/kg) in infected and
control mice (n = 6).
Tmax (h) Cmax T1/2 (h) Cl (L/h) Vd (L/kg) AUC0−24h
Plasma (mg/L) (mg·h/L)
Infected 0.75 17.3 ± 6.6 1.9 0.02 3.5 27.1
Control 1 6.7 ± 1.2 1.1 0.08 6.5 9.5
Brain tissue (µg/g of brain) (µg·h/g of brain)
Infected 0.75 2.0 ± 0.2 21.7 3.3
Control 1 0.8 ± 0.3 10.7 1.0
rate <11% for plasma and <10% for brain, and recovery
ranged from 99% to 103% for plasma and from 100% to
105%forbrain).Moxiﬂoxacinalsoremainedstable18hafter
sample treatment (CV < 5%, recovery between 98% to 105%
for plasma and 99% to 106% for brain).
3.2. Pharmacokinetic Study. The methods described above
were utilised in the determination of mean moxiﬂoxacin
concentrations from plasma and the CNS after a single
i.p. injection (50mg/kg) in L. monocytogenes infected and
control mice. The pharmacokinetic proﬁles are represented
in Figures 3(a) and 3(b), and the parameters determined for
moxiﬂoxacin are shown in Table 2.
In plasma, for infected mice, the moxiﬂoxacin Cmax was
reached at 0.75h (Cmax 17.3 ± 6.6mg/L) versus 1h (Cmax
6.7 ± 1.2mg/L) for the control group. Nevertheless, after
1 hour, the concentration of moxiﬂoxacin rapidly dropped
and became undetectable after 8 hours (versus 6 hours for
the control group). The plasma AUC24 was 27.1mg·h/L and
9.5mg·h/L in infected and control mice, respectively. The
AUC24/MIC ratio (AUIC) for moxiﬂoxacin was 54, and the
Cmax/MIC ratio was 34 in infected mice.
In cerebral tissue, moxiﬂoxacin was quickly detected (5
minutes) and its concentration peaked at 2.0 ± 0.2µg/g
(compared with 0.8 ± 0.3µg/g in the control group) within
1 hour of i.p. administration. After 0.75h, the cerebral con-
centration of moxiﬂoxacin decreased, but was still detectable
8 hours after administration (versus 6 hours in controls).
The cerebral AUC24 was 3.3µg·h/g and 1.0µg·h/g
in infected and control mice, respectively. The AUCbrain/
AUCplasma ratio was always greater than 0.1.
4. Discussion
In this study, we described a HPLC method to quantify
moxiﬂoxacin penetration in plasma and brain. Optimization
of the method of Ba et al. was performed by modifying
several preanalytical and analytical steps [9]. In particular,
we assessed and ﬁne-tuned the pH and composition of
the mobile phase, SDS concentration, addition of TBABr,
and detection mode. Mouse plasma and brain samples
were processed by deproteinization with acetonitrile due to
the low-protein binding of moxiﬂoxacin [1]. Due to the
extractioneﬃciency,wedecidedtovalidatethemethodusing
ciproﬂoxacin as an internal standard.
Separation was achieved by ion-pairing reversed-phase
chromatography with a 10mM concentration of SDS
[11]. Liang et al. showed that above this concentration,Journal of Analytical Methods in Chemistry 5
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Figure 3: (a) Plasma concentration time course (mg/L) of moxiﬂoxacin in mice (infected  or not ) after a single i.v. administration of
50mg per kg of bodyweight (bolus injection) (n = 6); (b) brain concentration time course (µg/g of brain) of moxiﬂoxacin in mice (infected
 or not ) after a single i.v. administration of 50mg per kg of body weight (bolus injection) (n = 6).
ﬂuoroquinolone resolution was not improved and column
equilibration time was optimum. Competing-base agent
(TBABr) was added at the concentration of 10mM to
increase resolution between moxiﬂoxacin and ciproﬂoxacin,
and to improve the peak shape [9, 11]. The pH of the
mobile phase was ﬁxed at 3.5 with citric acid buﬀer at a
concentration of 25mM [11]. Finally, the optimized mobile
phase consisted of 10mM TBABr, 10mM SDS, 25mM citric
acid, 40% acetonitrile, and 3% methanol at pH 3.5. Due
to the properties of moxiﬂoxacin and ciproﬂoxacin, ﬂuo-
rescence detection was used because of its better sensitivity
and speciﬁcity than UV detection in complex matrix for
pharmacokinetic studies.
The HPLC method based on standard chromatographic
conditions, rapid sample preparation and analysis (less than
10min) has been developed for a dual-matrix moxiﬂoxacin
determination (plasma and cerebral tissue). The lower LOQ
was found to be 5µg/L in plasma and 0.1µg/g in brain.
The LOQ in plasma is similar to that reported in recent
studies [10, 18]. Moreover, we did not need derivatization
with a ﬂuorescent molecule [19]. In plasma and brain
tissue, it is low enough to enable pharmacokinetic studies
in mice, other animals, or humans. This HPLC method
is helpful and essential to study the pharmacokinetics and
cerebral penetration of moxiﬂoxacin. Several methods have
been described for moxiﬂoxacin quantiﬁcation in diﬀerent
matrices (plasma, urine, cerebrospinal ﬂuid, peritoneum,
lung, etc.) [11, 14, 20]. However, most of these methods are
described for only one matrix and some of them have very
high LOQ (90µg/L for the method described by Hemanth
Kumar and Ramachandran) [18] which are not suitable for
pharmacokinetic studies in mice.
To our knowledge, this study is the ﬁrst to evaluate mox-
iﬂoxacin brain penetration by measuring concentrations in
a murine model of cerebral listeriosis after i.p. treatment.
Rodriguez-Cerrato et al. determined moxiﬂoxacin CSF pen-
etration in a rabbit model of Escherichia coli meningitis
[14]. Kanellakopoulou et al. showed the pharmacokinetics of
moxiﬂoxacin in noninﬂamed CSF of humans [13, 14]. These
two studies investigated moxiﬂoxacin pharmacokinetics in
CSF. In contrast, we have investigated moxiﬂoxacin phar-
macokinetics in plasma and brain tissue due to the intra-
cellular development of L. monocytogenes. Subsequently, we
have shown modiﬁcation of moxiﬂoxacin pharmacokinetics
between infected or control mice (plasma and brain data).
Moxiﬂoxacin brain penetration was shown according
to its presence in CSF, as highlighted by Rise et al. [21].
Indeed, plasma and CNS tissue kinetics increased by 2.9 and
3.3 times, respectively, between control and infected mice
(Cmax,half-life,AUC0−24h).Inﬂammationofthebrain-blood
barrier could explain the increase of these parameters in
brain but not in plasma. The increase in plasma could be due
to a diminution of hepatic metabolism or renal elimination
due to infection by L. monocytogenes.
Our study is not without limitations including the
omission of weighing animals before and after infection with
L. monocytogenes to determine potential dehydration, which
could account for the increase in plasma concentrations of
moxiﬂoxacin in infected compared with control mice. Also,
we did not quantitate the concentration of moxiﬂoxacin in
the CSF of mice to distinguish between diﬀusion in the
blood-brain barrier and diﬀusion in brain tissue. Finally,
we did not determine the concentration of moxiﬂoxacin
in urine; a reduction in renal elimination of moxiﬂoxacin
in infected mice might explain the increased serum moxi-
ﬂoxacin concentration in infected animals.
As Grayo et al. showed, AUIC (AUCplasma/MIC) is the
most relevant parameter to demonstrate in vivo eﬃciency.
For ﬂuoroquinolones, an AUIC value that appears suﬃcient
in vitro and in animal and clinical trials, and for other
infections, is between 30 [22] and 125 [23]; in our study
it was equal to 54 and could explain the eﬃcacy of
moxiﬂoxacin in CNS listeriosis [7]. In contrast to Alﬀenaar
et al., we assessed cerebral penetration by determination of
the AUCbrain/AUCplasma ratio, and not the AUCCSF/AUCplasma
ratio, which is the more relevant quantitative marker of
antibacterialdiﬀusionintissue[24].Theseratioswer eal wa ys
greater than 0.1, varying from plasma to brain. Even if the
AUCbrain/AUCplasma ratio is not high, the AUIC in brain is
enough to explain the in vivo eﬃcacy of moxiﬂoxacin [7].6 Journal of Analytical Methods in Chemistry
Subsequently, we showed diﬀusion of moxiﬂoxacin (5 min-
utes after injection) in cerebral tissue in infected mice unlike
amoxicillin, considered in [6]. This rapid diﬀusion is proba-
bly related to increased blood-brain barrier permeability due
to the inﬂammation of the meninges resulting in prolonged
detectionofthedruginthebraintissue[7,21,25].Moreover,
moxiﬂoxacin can be detected 8 hours after administration in
infected mice and 6 hours in control mice. This conﬁrms
the good level of brain penetration of moxiﬂoxacin as
demonstrated by Wise et al. [21] and it could explain the in
vivo eﬃciency [7].
5. Conclusion
We have developed and validated a HPLC moxiﬂoxacin
determinationmethod inplasmaandbraintissueinamouse
model. Based on this sensitive method, we demonstrated
moxiﬂoxacin penetration in the CNS for the ﬁrst time in
this listeriosis model. As expected, we suggest that infection
can modulate the pharmacokinetic proﬁle of moxiﬂoxacin.
Indeed, the higher antimicrobial concentrations can be cor-
related with improved diﬀusion into infected tissue (plasma
and cerebral) in listeriosis than in a healthy model. This
could explain the systemic antimicrobial in vivo eﬃciency of
moxiﬂoxacin against L. monocytogenes. Further, clinical data
are required to conﬁrm these ﬁndings.
Due to an excellent separation eﬃciency, sensitivity by
ﬂuorescent detection and its simplicity, this HPLC method
could potentially meet the analysis requirements for any
othercomplextissues(suchasliverorlung),orfortherapeu-
tic drug monitoring of moxiﬂoxacin in other human diseases
(such as cholecystitis or tuberculosis).
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